Roche ends work on tominersen after decade of trials, as well as early-stage Huntington’s asset

After more than a decade of work and plenty of ups and downs, Roche has dropped its Huntington’s disease drug tominersen. The decision comes after tominersen did no better than placebo in a Phase 2 …

Source: Endpoints News